Drug eluting stent

Browse trials
V2  
List  

treatment    comparator  All cause death MACE Long term death  myocardial infarction (fatal and non fatal)  cardiac death Stent thrombosis (any, end of follow up) Stent thrombosis (any, end of follow up) target lesion revascularisation  angiographic restenosis  4 yr mortality from all causes  4 yr TLR  4 yr MI 4 yr death or MI  4 yr stent thrombosis 4y stent thrombosis (ARC) CABG long term MI  1 year MI  1 year death from any cause  late stent thrombosis (31days - 1year) target-vessel revascularization 2 yr TLR  2 yr MACE  in-lesion binary restenosis  2 yr Death (all cause)  Acute stent thrombosis (<=24h) sub acute stent thrombosis (1-30 days)  1 year event 6 months MI 6 months events 1 year revascularization 6 months death long term cardiovascular events     
Abciximabcoronary artery disease, in all type of patients vs bare-metal stent----------------------------------
Biolimus eluting stentcoronary artery disease, in all type of patients vs sirolimus eluting stentNSNS-NSNSNSNSNSNS------NS---NSNS-------------
Biolimus eluting stentcoronary artery disease, in unparticular patients vs sirolimus eluting stentNSNS-NSNSNSNSNSNS------NS---NSNS-------------
Candesartancoronary artery disease, in unprotected left main artery stenosis vs CABGNSNS-NS---------------- by 45% -------------
Dactinomycin eluting stentcoronary artery disease, in all type of patients vs bare-metal stentNS by 93% -NS---NS------- by 91% ------------------
Dactinomycin eluting stentcoronary artery disease, in unparticular patients vs bare-metal stentNS by 93% -NS---NS------- by 91% ------------------
Drug-eluting stentscoronary artery disease, in all type of patients vs bare-metal stent-NS-NS---NS------NS-------------------
Drug-eluting stentscoronary artery disease, in all type of patients vs CABGNS- by 36% -----------------NS-NS---------- by 39%
Drug-eluting stentscoronary artery disease, in acute myocardial infarction vs bare-metal stentNS by 41% -NSNSNSNSNS--NSNS-NSNS----- by 61% by 63% by 37% -NS---------
Drug-eluting stentscoronary artery disease, in unprotected left main artery stenosis vs CABGNS-------------------NS-------------
Everolimus eluting stentcoronary artery disease, in all type of patients vs bare-metal stentNSNS-NSNSNSNSNS------NS----- by 64% -NS-NS---------
Everolimus eluting stentcoronary artery disease, in all type of patients vs everolimus eluting stent----------------------------------
Everolimus eluting stentcoronary artery disease, in all type of patients vs paclitaxel eluting stentNS by 40% - by 42% NS by 69% by 69% by 50% ------ by 61% NS---NS by 42% by 35% by 34% --NS by 90% -------
Everolimus eluting stentcoronary artery disease, in all type of patients vs sirolimus eluting stent-----NSNS--------------NSNS-----------
Everolimus eluting stentcoronary artery disease, in unparticular patients vs bare-metal stentNSNS-NS-NSNSNS--------------------------
Everolimus eluting stentcoronary artery disease, in unparticular patients vs paclitaxel eluting stentNS by 40% - by 42% NS by 69% by 69% by 50% ------ by 61% NS---NS by 42% by 35% by 34% --NS by 90% -------
Everolimus eluting stentcoronary artery disease, in unparticular patients vs sirolimus eluting stent-----NSNS--------------NSNS-----------
Everolimus eluting stentcoronary artery disease, in small vessels vs paclitaxel eluting stentNS by 74% -NSNSNSNS by 90% -------NS---- by 80% -------------
Paclitaxelcoronary artery disease, in all type of patients vs bare-metal stentNS by 25% -NSNSNSNS by 52% by 63% -NSNS-NS-----NS by 38% by 42% NS by 70% NSNSNS-------
Paclitaxelcoronary artery disease, in all type of patients vs balloon angioplastyNS--NS----------------NS-------------
Paclitaxelcoronary artery disease, in all type of patients vs CABGNS by 50% -NS by 82% NSNS by 132% ------NS by 126% --- by 57% - by 103% by 44% -NSNS by 496% -------
Paclitaxelcoronary artery disease, in diabetic patients vs bare-metal stent------- by 59% by 83% -------------------------
Paclitaxelcoronary artery disease, in diabetic patients vs sirolimus eluting stent----------------------------------
Paclitaxelcoronary artery disease, in acute myocardial infarction vs bare-metal stentNSNS-NS-NSNS by 39% by 56% -NSNS-NS------ by 35% by 42% NS-NS---------
Paclitaxelcoronary artery disease, in long or complex lesion vs bare-metal stentNS by 30% -NS-NSNS by 45% by 57% ----------- by 30% ----NSNS-------
Paclitaxelcoronary artery disease, in long or complex lesion vs CABGNS by 50% -NS by 82% NSNS by 132% ------NS by 126% --- by 57% - by 103% by 44% -NSNS by 496% -------
Paclitaxelcoronary artery disease, in bypass graft lesion vs bare-metal stentNSNS-NS-NSNS by 83% ------------NS-------------
Paclitaxelcoronary artery disease, in in stent restenosis vs brachytherapy----------------------------------
Paclitaxelcoronary artery disease, in unprotected left main artery stenosis vs bare-metal stentNSNS-NSNS-- by 88% --------------------------
Paclitaxelcoronary artery disease, in unparticular patients vs bare-metal stentNS by 34% -NSNSNSNS by 72% by 68% ----------NS by 50% -- by 70% --NS-------
Paclitaxelcoronary artery disease, in small vessels vs bare-metal stent----------------------------------
Sirolimus eluting stentcoronary artery disease, in all type of patients vs bare-metal stentNS by 62% - by 33% NSNSNS by 74% by 81% -----NS by 58% ---NS by 59% NS by 44% --NSNS-------
Sirolimus eluting stentcoronary artery disease, in all type of patients vs balloon angioplastyNS--NS---------------- by 76% -------------
Sirolimus eluting stentcoronary artery disease, in all type of patients vs paclitaxel eluting stentNS by 25% -NSNSNSNS by 31% by 32% ----- by 33% NS---NS by 40% --NS-NSNS-------
Sirolimus eluting stentcoronary artery disease, in all type of patients vs CABG----------------------------------
Sirolimus eluting stentcoronary artery disease, in all type of patients vs MIDCAB----------------------------------
Sirolimus eluting stentcoronary artery disease, in diabetic patients vs bare-metal stentNS by 55% -NS-NSNS by 75% by 88% ------NS---NS by 75% by 78% by 69% --NSNS-------
Sirolimus eluting stentcoronary artery disease, in diabetic patients vs paclitaxel eluting stentNSNS-NSNSNSNS by 36% by 75% -----NSNS---NSNS-- by 79% -NSNS-------
Sirolimus eluting stentcoronary artery disease, in acute myocardial infarction vs bare-metal stentNS by 52% -NSNSNSNS by 64% by 72% -----NSNS---- by 60% - by 35% ---NS-------
Sirolimus eluting stentcoronary artery disease, in acute myocardial infarction vs paclitaxel eluting stentNSNS-NSNSNSNSNS------NS----NSNS----NSNS-------
Sirolimus eluting stentcoronary artery disease, in long or complex lesion vs bare-metal stentNS by 86% -NS-NSNS by 87% by 87% ----------- by 64% -------------
Sirolimus eluting stentcoronary artery disease, in long or complex lesion vs paclitaxel eluting stentNS--NSNSNSNS by 38% by 75% -----NS----- by 58% -------------
Sirolimus eluting stentcoronary artery disease, in bypass graft lesion vs bare-metal stentNSNS-NS---NS------------ by 81% NSNS- by 2139% ---------
Sirolimus eluting stentcoronary artery disease, in in stent restenosis vs PTCANS by 62% -NS-NSNS------------- by 65% -------------
Sirolimus eluting stentcoronary artery disease, in in stent restenosis vs brachytherapyNS by 48% -NS-NSNS by 56% ------- by 92% ---- by 50% -------------
Sirolimus eluting stentcoronary artery disease, in in stent restenosis vs paclitaxel eluting stentNS--NS-NSNS-------NS-----NS-------------
Sirolimus eluting stentcoronary artery disease, in unprotected left main artery stenosis vs paclitaxel eluting stentNSNS-NS----NS-------------------------
Sirolimus eluting stentcoronary artery disease, in bifurcation lesion vs paclitaxel eluting stentNS--NS--- by 70% --------------------------
Sirolimus eluting stentcoronary artery disease, in unparticular patients vs bare-metal stentNS by 60% -NS-NSNS by 74% by 81% ------NS---NS by 59% ----NS--------
Sirolimus eluting stentcoronary artery disease, in unparticular patients vs paclitaxel eluting stentNSNS-NSNSNSNSNSNS-----NSNS---NSNS--NS-NSNS-------
Sirolimus eluting stentcoronary artery disease, in total occlusion vs bare-metal stentNS by 83% -NS-NSNS by 79% by 85% ----------- by 73% by 453% ------------
Sirolimus eluting stentcoronary artery disease, in small vessels vs bare-metal stentNS by 70% - by 80% -NSNS by 67% by 82% ------NS------------------
Sirolimus eluting stentcoronary artery disease, in small vessels vs paclitaxel eluting stentNS by 51% -NSNSNSNS by 52% ------NSNS---- by 60% -------------
Zotarolimus eluting stentcoronary artery disease, in all type of patients vs bare-metal stent- by 50% ---NSNS- by 61% -------------------------